tbuckley/cabot-search huggingface dataset:
Phase I study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC)
Authors: P. Koralewski, M. Blasinska Morawiec, A. Tekiela, E. Chmielowska, M. Campone, J. Bonneterre, B. Longerey, S. Lafaye de Micheaux
Journal: Journal of Clinical Oncology (2004)

684 Background: VRL and DTX target tubulin-microtubule system, either inhibiting tubulin polymerisation (VRL) or microtubule depolymerisation (DTX). Both agents have proven activity in MBC. Methods: The aim of this study was to determine the recommended dose and regimen (RD) of i.v. VRL and DTX given on day 1 (D1) and oral VRL on D8 or 15 every 3 weeks, for a maximum of 6 cycles. Three to six patients (pts) per cohort were treated. Dose-limiting toxicity (DLT) was assessed during the first cycle and defined as grade 4 neutropenia ≥ 7 days, grade 3 thrombocytopenia, neutropenic infection, febrile neutropenia, any grade > 2 non-haematological toxicity except asthenia and inadequately treated nausea/vomiting and diarrhoea, omission of oral VRL, and a delay of ≥ 1 week in starting cycle 2 for haematological reason. Results: Thirty pts were treated in 6 cohorts. Median age was 61 years, CT as neoadjuvant or adjuvant were given to 50% of pts and 73.3% of pts had a visceral involvement. Four pts were non evaluable for MTD: three had received GCSF, and the oral dose of one was underestimated at cycle one. The DLT reported were: omissions of oral VRL for haematotoxicity (11 pts), febrile neutropenia (2 pts) and grade 4 neutropenia ≥ 7 days (2 pts). The RD is dose level IV (see in table). Two partial responses were seen among the 6 pts treated at RD. Conclusion: This phase I study has established a RD of VRL (20 mg/m2 of the i.v. form on D1 and 60 mg/m2 of the oral form on D15) and DTX (60 mg/m2 on D1). Based on interesting clinical responses observed during phase I, a phase II study is ongoing. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Institut de recherche Pierre Fabre Aventis; Institut de recherche Pierre Fabre
Ventricular Tachycardia Associated With Non-Freon Aerosol Propellants
Authors: Suman Wason
Journal: JAMA (1986)

A previously well 2-year-old child presented with seizures and ventricular tachycardia shortly after playing with an aerosol can of a well-known proprietary deodorant. She required intensive care and survived without sequelae. The propellants used in this product were isobutane,<i>n</i>-butane, and propane. The propellants have been thought to be safer than the previously used Freons, which were known to be cardiotoxic and neurotoxic. Significant exposure was confirmed by the detection of<i>n</i>-butane and isobutane in the patient's serum. We conclude that unintentional exposure to non-Freon aerosol propellants in a nonconfined space can be hazardous to children. Aerosol cans should be considered to represent toxic hazards and should be kept out of reach of children. (<i>JAMA</i>1986;256:78-80)
Theatre: Oxygen
Authors: T. Jackson
Journal: BMJ (2001)

By Carl Djerassi and Roald Hoffman Riverside Studios, London W14, until 1 December (http://www.riversidestudios.co.uk/) Rating: ![Graphic][1]</img>![Graphic][2]</img> Is science about advancing human knowledge or enhancing the reputation of scientists? How do you decide whom to credit for a scientific or medical breakthrough, when progress in these fields is incremental and often collaborative? What criteria do those who hand out gongs, such as Nobel prizes, use to reach their decisions? Carl Djerassi, coauthor of this short play, has long been asking such questions. Over the past 14 years, he has written five novels in a genre he calls “science-in-fiction,” exploring the human side of scientific discovery and the personal trials and tribulations scientists go through in their … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif
Prison Break
Authors: Jack Coulehan
Journal: Annals of Internal Medicine (2017)

Ad Libitum19 September 2017Prison BreakJack Coulehan, MD, MPHJack Coulehan, MD, MPHFrom Setauket, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-0433 Audio Reading - “Prison Break” Audio. Virginia L. Hood, MD, Annals Associate Editor, reads "Prison Break," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I eavesdrop on the cells in your brain,which are trying to bust out of a prisonsurrounded by broken connections.They make an almost inaudible humbeneath mechanical whooshes and pingssurrounding your hospital bed. I listenwhile sitting with your hand in mine,not comforted by the confusionof intensive care—I know your brainis scheming, despite these machinesand my heartache, to escape. Its intentionis clear—get out while there is still time.Some of the doctors say, She's young and strong.Do the tunnelers in your brain hear them?I eavesdrop—the messages you send are thinroutes to escape ... Author, Article, and Disclosure InformationAffiliations: From Setauket, New York.Current Author Address: Jack Coulehan, MD, MPH; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement Audio Reading - “Prison Break” Audio. Virginia L. Hood, MD, Annals Associate Editor, reads "Prison Break," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 19 September 2017Volume 167, Issue 6Page: 431KeywordsBrainCells ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
SPECIFIC PRECIPITIN FOR BENCEJONES PROTEIN
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response to Comment on: Jeon et al. <i>Helicobacter pylori</i> Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520–525
Authors: Christie Y. Jeon, Mary N. Haan, Caroline Cheng, Erin R. Clayton, Elizabeth R. Mayeda, Joshua W. Miller, Allison E. Aiello
Journal: Diabetes Care (2012)
TBIO-21. ANALYSIS OF PAIRED BRAFV600E MUTANT GLIOMA PATIENT SAMPLES IDENTIFIES NOVEL RESISTANCE MECHANISMS TO TARGETED BRAF INHIBITION
Authors: Jean Mulcahy Levy, Bridget Sanford, Andrew Morin, Adam Green, Patrick Flannery, Kenneth Jones, Anurhada Banerjee, Kellie Nazemi, David Samuel, Lindsay Kilburn, David Solomon, Theodore Nicolaides
Journal: Neuro-Oncology (2018)

BRAFV600E mutations occur in a variety of gliomas and BRAFV600E targeted therapies have provided new treatment options. Trials in melanoma and colorectal cancer, as well as early results in CNS tumors, indicate a high risk for the development of resistance. To date there is little data available for resistance mechanisms in glioma patients treated with BRAFV600E inhibition. To identify molecular and pathway alterations driving resistance, we performed targeted next-generation DNA sequencing, RNA sequencing, and Ingenuity Pathway Analysis (IPA) on paired pre-treatment and post-resistance primary pediatric glioma samples (n=10) and cell lines (n=2). Unique genetic alterations likely driving tumor recurrence and resistance to BRAF inhibition were identified. Novel mutations in post-resistance samples included a de novo mutation in the CBL gene within the RING finger domain of the E3 ubiquitin ligase protein that has been recurrently found in myeloid neoplasms, a frameshift mutation in the RB1 tumor suppressor gene, and a nonsense mutation in ERRFI1, which encodes a negative regulator of EGFR signaling. IPA analysis demonstrated significant pathway activation differences in post-resistance samples. There was a predominance of upregulated receptor tyrosine kinase pathways including EGFR, NTRK2, TGFB1, estrogen receptor, ERBB2, and PI3K. Expected up-regulation of MEK, MAPK1, MAP2k1 and ERK1/2 pathways were found. The altered pathways were unique for each paired set. These data suggest that pediatric gliomas develop resistance to BRAF inhibition using a multitude of genetic and transcriptional mechanisms that are potentially distinct in each tumor, and with novel resistance mutations not found in resistant melanoma or colorectal cancers.
Commentary
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1952)

ANY QUESTIONS?1873) "I had the opportunity of showing to the late Dr. Leared that I had anticipated him in the invention of a binaural stethoscope; but his was much better than mine, through the addition of an india-rubber spring.The binaural instrument has some advantages in facility of application ;fbut it by no means transmits the chest sounds so simply, or faithfully, as the straight tube.I could never avail myself of its use; for during the last 20 or 30 years, the hearing of one ear has been defective.I have found the same to be the case with many of my brother auscultators."Sir Robert Young's presidential address to the Medi- cal Society of London' is a comprehensive account of the early history of the stethoscope.
Diagnostic Ultrasound
Authors: George R. Leopold
Journal: JAMA (1976)

<h3>To the Editor.—</h3> Dr Judith Everett's letter (235:2813, 1976) does an injustice to the rapidly developing science of diagnostic ultrasound. Numerous publications have verified a 95% accuracy figure in differentiating renal cysts and neoplasm by this technique. None of these publications has advocated using only ultrasound as the definitive method; cyst puncture is usually recommended to confirm suspected cysts and angiography is recommended to confirm solid neoplasms. In the case mentioned, followup percutaneous aspiration would have provided the correct information necessary for proper clinical management. While I am certainly aware that a small percentage of diagnostic errors can be made and that the quality of ultrasonic examinations varies throughout the country, to use an experience such as this to condemn ultrasound in a major publication such asThe Journalis both unfair and unnecessary. The real danger is that such public notice may result in the withholding of these studies
Lipopolysaccharide-neutralizing antibody reduces hepatocyte injury from acute hepatotoxin administration
Authors: M Czaja
Journal: Hepatology (1994)

Endogenous lipopolysaccharide has been implicated as a cofactor in the hepatocellular injury and death resulting from toxic liver injury. To prevent this lipopolysaccharide-induced injury and to further understand the mechanism of this effect, an anti-lipopolysaccharide antibody was administered to rats in which toxic hepatocellular injury was induced. Rats were given the hepatotoxin galactosamine together with an isotypic control antibody B55 or the anti-lipopolysaccharide antibody E5. E5 treatment resulted in reductions of serum AST levels of 43% at 36 hr (p<0.02) and 60% at 48 hr (NS) after galactosamine administration. These decreases in AST values were accompanied by diminished histological evidence of injury and inflammation. In carbon tetrachloride-induced liver injury, E5 similarly reduced serum AST levels at 36 and 48 hr by 47% (p<0.04) and 54% (p<0.03), respectively. E5 treatment was equally effective in reducing AST levels 48 hr after administration of carbon tetrachloride, whether the initial dose of antibody was given 1 hr before or 3 or 6 hr after the administration of this toxin. To understand the mechanism of this E5 effect, the activation of the toxic cytokine tumor necrosis factor-α and the chemotactic cytokine monocyte chemoattractant protein 1 was examined by Northern-blot analysis of RNA from rat livers after galactosamine-induced injury and treatment with B55 or E5. Despite E5's efficacy in reducing hepatocellular damage, E5 treatment did not affect the timing or magnitude of tumor necrosis factor-α or monocyte chemoattractant protein 1 activation during galactosamine-induced injury. These data suggest that antibody neutralization of lipopolysaccharide may be an effective therapy for toxic liver injury and that the mechanism of this effect is not through the prevention of cytokine expression. (HEPATOLOGY 1994;19:1282–1289.)
Testing Respiratory Protective Equipment for Approval
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Very-low-calorie diets
Authors: Paul D. Thompson
Journal: JAMA (1990)

<h3>To the Editor.—</h3> In a recent<i>JAMA</i>commentary, Wadden et al<sup>1</sup>addressed the "responsible and irresponsible use of very-low-calorie diets in the treatment of obesity." In the section on long-term changes, we learn that patients 1 year after the diets have regained 33% or 67% of their lost weight, depending on whether they did or did not receive concomitant behavioral therapy. Is that it for long-term evaluation—1 year? Will all patients be just as fat 18 or 36 months later despite referral to responsible programs? These diet programs are expensive even when the costs of wardrobe adjustments are not considered. Perhaps the whole business is irresponsible until we know the long-term efficacy of these diets, their risks, and the metabolic effects of marked variations in body weight.
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Authors: D. J. Schwartzentruber, D. Lawson, J. Richards, R. M. Conry, D. Miller, J. Triesman, F. Gailani, L. B. Riley, D. Vena, P. Hwu
Journal: Journal of Clinical Oncology (2009)

CRA9011 Background: In a phase II study, 13 (42%) of 31 patients with metastatic melanoma receiving high-dose (HD) IL-2 plus gp100:209–217(210M) peptide experienced objective responses (S.A. Rosenberg, et al, Nature Medicine 4: 321–327, 1998). Other studies showed a lower response rate (RR) but no randomized studies have been done. Methods: A prospective randomized phase III trial was conducted at 21 centers with 185 patients. Eligibility: stage IV or locally advanced stage III cutaneous melanoma, HLA A0201, no brain metastases, eligible for HD IL-2, and no previous HD IL-2 or gp100:209–217(210M). Arm 1 received HD IL-2 alone (720,000 IU/kg/dose) and Arm 2 gp100:209–217(210M) peptide + Montanide ISA followed by HD IL-2. The primary objective was clinical response. Secondary objectives were toxicity, disease free/progression free survival, immunologic response and quality of life. Central HLA typing, pathology review, and blinded response assessment were done at the NIH. Central data monitoring was done by The EMMES Corp. and a Data Safety Monitoring Board. Results: Numbers of patients enrolled, treated, and evaluable for response in Arm 1 were 94, 93, and 93 respectively; in Arm 2 91, 86, and 86. Toxicities were consistent with HD IL-2 ± vaccine. Investigator assessed RR showed significant improvement in overall RR for Arm 2=22.1% vs 9.7% (P=0.0223, Chi-Square) and progression free survival (PFS) in favor of Arm 2=2.9 months (1.7–4.5) vs 1.6 (1.5–1.8) (P=0.0101). Median overall survival favors Arm 2=17.6 months (11.8–26.6) vs 12.8 (8.7–16.3) (P=0.0964). Blinded response review is ongoing. Conclusions: RR and PFS were superior with peptide vaccine and HD IL-2 compared to HD IL-2 alone. This represents the first evidence of clinical benefit of vaccination in patients with melanoma. [Table: see text]
Dietary Sources of Long-Chain n-3 Polyunsaturated Fatty Acids-Reply
Authors: David S. Siscovick
Journal: JAMA (1996)

<h3>In Reply.</h3> —Dr Siguel suggests that consumption of seafood is not the primary dietary source of the long-chain n-3 PUFAs EPA and DHA. Among vegetarians and persons who consume low amounts of linoleic acid (C<sub>18:2n-6</sub>), dietary intake of alphalinolenic acid (C<sub>18:3n-3</sub>) from other foods such as tofu, soybean oil, and canola oil may increase cell membrane levels of EPA.<sup>1</sup> The purpose of our study was to assess the relation of the dietary intake and cell membrane levels of long-chain n-3 PUFAs derived from seafood and the risk of primary cardiac arrest in the community. In Seattle, Wash, seafood such as salmon, which is high in long-chain n-3 PUFAs, is an important component of the diet. As we noted, there was a strong correlation between dietary intake of long-chain n-3 PUFAs from seafood and red blood cell membrane long-chain n-3 fatty acid levels. The mean (SD) red blood
Experimental Bacterial and Chemical Pollution of Wells via Ground Water and the Factors Involved. Report on the Geology and Ground Water Hydrology of the Experimental Area of the United States Public Health Service at Fort Caswell, N. C.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recent Achievements and Research Initiated in the Swedish Plastics and Rubber Industry
Authors: Anders Englund, Bo Holmberg
Journal: Environmental Health Perspectives (1976)

The improvement in exposure conditions in the Swedish vinyl chloride producing industry is reported. The article comments on the technology and control methods by which the vinyl chloride concentration has been lowered to less than 1 ppm vinyl chloride. Two epidemiological retrospective cohort studies are presently under way on workers in PVC-utilizing industries and in the rubber industry.
Premature coronary artery disease: 15-year follow-up in patients under the age of forty Joseph I. Miller, III, Laurence S. Sperling, Abdolreza Agahtehrani, Chris Nell, William S. Weintraub. Section of Preventive Cardiology, Division of Cardiology, Emory University, Atlanta, GA, Emory Center for Outcomes Research, Atlanta, GA
Journal: Journal of the American College of Cardiology (2001)
Turner-mongolism polysyndrome. Review of the first eight known cases
Authors: M. M. Villaverde
Journal: JAMA (1975)

To date, a total of eight cases of the Turner-mongolism polysyndrome have been recognized. The clinical manifestations include retarded growth (resulting in a small and infantile appearance), with shield-like chest, poorly developed breasts, absent body hair, brachycephaly, short neck with foldings and low hairline, oblique eyes with epicanthal folds, squat nose, scrotal or normal tongue, abnormal hard palate (high or cleft), short hands and feet, frequent cubitus valgus, normal clitoris (may be either hypoplastic or peniform), mental retardation, and the XO/G+ karyotype, mosaic for XO in most instances. At this time, a single cause for all cases of the double aneuploidy is not known. (<i>JAMA</i>234:844-847, 1975)